Viewing nowCombinationPoshuvet Duo Sustained Release Tablet 10/1000 Milligrams
Dapagliflozin citric acid 14.7mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Genewon Science Co., Ltd.

MFDS item code 202107126 · Approved 2021.10.26 · Insurance code 671707070
Improvement of glycemic control in adults with type 2 diabetes mellitus
This medication is prescribed for patients with type 2 diabetes whose blood sugar control is insufficient despite lifestyle changes, using dapagliflozin and metformin together. It is particularly important to use this medication cautiously in patients with cardiovascular disease or risk factors, and detailed clinical information should be referenced from expert guidelines. Overall, this medication is effectively used to improve blood sugar control in patients with type 2 diabetes.
The dose of this medicine should be individualized based on the patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of dapagliflozin 10mg and extended-release metformin 2000mg. This medicine is generally administered once daily with the evening meal. The maximum dose of this medicine is dapagliflozin 10mg/extended-release metformin 2000mg once daily, given as 2 tablets of 5mg/1000mg. Patients who have not previously received pharmacologic treatment for diabetes and whose blood glucose is not adequately controlled with monotherapy: When used as initial therapy in patients who have not previously received pharmacologic treatment for diabetes, the recommended starting dose of this medicine is 1 tablet of 5mg/500mg or 10mg/500mg once daily. Titrate the dose gradually to reduce gastrointestinal adverse reactions to metformin. For patients receiving metformin, the recommended dose of dapagliflozin is 10mg once daily, and the dose of this medicine should provide the patient's current metformin dose or an appropriately adjusted dose therapeutically close to it. When switching from immediate-release to extended-release metformin, blood glucose control should be closely monitored and the dose adjusted appropriately. For patients switching from combination therapy with dapagliflozin and metformin to this medicine, treatment may be started at the doses of dapagliflozin and metformin previously being taken. When switching from immediate-release to extended-release metformin, blood glucose control should be closely monitored and the dose adjusted appropriately. When this medicine is used in combination with insulin or an insulin secretagogue such as a sulfonylurea, a lower dose of insulin or the insulin secretagogue may be considered to reduce the risk of hypoglycemia. The safety and efficacy of this medicine have not been specifically evaluated in patients switching to it from other glucose-lowering medicines. Because such a change may cause alterations in blood glucose control, any changes in the treatment of patients with type 2 diabetes should be made with careful monitoring. This medicine must be swallowed whole and must never be crushed, cut, or chewed. Occasionally, inactive ingredients in this medicine may be excreted in the stool as a soft, hydrated mass resembling a tablet. Renal impairment No dose adjustment is necessary for patients with mild renal impairment. For patients with an estimated glomerular filtration rate (eGFR) of 45 mL/min/1.73 m2 or higher and less than 60 mL/min/1.73 m2 who do not have other conditions that may increase the risk of lactic acidosis, the starting dose of metformin hydrochloride, a component of this medicine, is 500mg once daily, and the maximum daily dose is 1000mg. Use of this medicine is not recommended in patients with an eGFR below 45 mL/min/1.73m2. If the estimated glomerular filtration rate (eGFR) falls below 45 mL/min/1.73m2, this medicine must be discontinued immediately. Renal function should be assessed every 3~6 months. Elderly patients Because metformin is excreted through the kidneys and renal function is more likely to decline in elderly patients, this medicine should be used with caution as age increases (see Precautions for Use, 9. Use in Elderly Patients).
This medication is a combination therapy used for the treatment of type 2 diabetes and helps in controlling blood sugar levels. It should not be administered to patients with impaired kidney function or those with acute illness. During treatment, a rare complication called lactic acidosis may occur, and if symptoms such as difficulty breathing, abdominal pain, or weakness arise, healthcare professionals should be notified immediately. This medication may cause hypoglycemia, so caution should be exercised when used alongside insulin or sulfonylurea medications. Elderly patients with reduced kidney function or in a state of dehydration should evaluate their fluid status and kidney function before starting this medication, and their condition should be regularly monitored after administration. This medication may increase the risk of genital and urinary tract infections, so prompt treatment is necessary if any infection symptoms appear. Women who are pregnant or may become pregnant, as well as nursing mothers, should not use this medication. Alcohol consumption should be avoided during treatment, as excessive drinking may increase the risk of lactic acidosis. Before undergoing surgery or radiographic studies using contrast agents, this medication should be discontinued for a period of time, and it should be resumed only after confirming normal kidney function. Vitamin B12 levels may decrease; therefore, regular blood tests are advisable during long-term use. In the event of overdose, immediate treatment at a medical facility is required, and this medication can be removed through dialysis. Store this medication out of reach of children and keep it in its original container for safety. Caution is required when driving or operating machinery, as dizziness may occur.
Not everyone experiences these, and they can vary from person to person.
Store this medication in a tightly closed container to prevent air or moisture. It is preferable to keep it at room temperature between 1 and 30 degrees Celsius. Proper storage will help maintain the medication's effectiveness for a longer period.
Yellow, double convex, film-coated tablet in the shape of a round pill.
30 tablets per bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowCombinationDapagliflozin citric acid 14.7mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Genewon Science Co., Ltd.
CombinationDapagliflozin citric acid 14.7mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
HK Inno.N Co., Ltd.
CombinationDapagliflozin citric acid 7.35mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
HK inno.N Co., Ltd.
Dapagliflozin citric acid 14.7mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Poonglim Pharmaceutical Co., Ltd.
Dapagliflozin citric acid 7.35mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Punglim Muhak Co., Ltd.
CombinationDapagliflozin citric acid 14.7mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Korea Prime Pharmaceutical Co., Ltd.
Dapagliflozin citric acid 7.35mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Korea Prime Pharmaceutical Co., Ltd.
CombinationDapagliflozin citric acid 14.7mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
KS Pharm Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.